Transformative Artificial Intelligence and Machine Learning Based Strategies to Identify Determinants of Exceptional Health and Life Span (R21/R33 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) will use the NIH Phased Innovation Award mechanism (R21/R33) to develop novel transformative artificial intelligence/machine learning (AI/ML) strategies and computer automation to integrate, extract, and interpret multi-omic (i.e., genome, epigenome, transcriptome, proteome, metabolome, microbiome, phenome) data sets from human exceptional longevity (EL) cohorts and multiple non-human species that display wide variation in life span and decipher the relationships between DNA, RNA, proteins, metabolites, and other cell variables, as well as links to disease risks and exceptionally healthy aging. The investigative team(s) for this FOA is/are expected to be multi-disciplinary, encompassing expertise in AI/ML, aging biology, comparative biology, and bio/chemo informatics. Investigative teams will design/develop intelligent and innovative algorithms and novel AI/ML based computational strategies during the R21 phase, then apply the developed AI/ML tools to complex, heterogenous multi-omic data sets from exceptional healthy aging human cohorts and non-human species in the R33 phase to discover novel protective molecular factors, biological process(es) and interlayer regulatory mechanism(s) that govern the exceptional aging process and develop translational strategies on omic-based therapeutic target(s) to prevent or delay age-related diseases including Alzheimer’s disease and Alzheimer's disease-related dementias (AD/ADRD) and enhance the human health span. This FOA strongly encourages collaboration (including public-private partnerships), coordination, data and resource exchange among researchers studying exceptional longevity and with related NIH-supported omics activities being pursued in different cohorts such as the Trans-Omics for Precision Medicine (TOPMED), the Accelerating Medicines Partnership-Alzheimer’s Disease (AMP-AD), and the Alzheimer’s Disease Sequencing Project (ADSP). Prospective applicants are strongly encouraged to contact NIA staff to discuss their proposed projects to ensure their responsiveness to this FOA. Applications using only the R21 mechanism or the R33 mechanism will not be accepted under this FOA.


  • Letter of Intent Due Date(s): September 28, 2021

  • Application: October 28, 2021

RFA-AG-22-022 Expiration Date October 29, 2021

Agency Website

Amount Description

Application budgets are not to exceed $150,000 in direct costs per year in the R21 phase and $350,000 in direct costs per year in the R33 phase.

Funding Type





Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

October 28, 2021